BG105599A - METHOD AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY - Google Patents
METHOD AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILYInfo
- Publication number
- BG105599A BG105599A BG105599A BG10559901A BG105599A BG 105599 A BG105599 A BG 105599A BG 105599 A BG105599 A BG 105599A BG 10559901 A BG10559901 A BG 10559901A BG 105599 A BG105599 A BG 105599A
- Authority
- BG
- Bulgaria
- Prior art keywords
- protein
- family
- compositions
- restoring
- wild
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11054298P | 1998-12-02 | 1998-12-02 | |
| PCT/IB1999/001916 WO2000032175A2 (fr) | 1998-12-02 | 1999-12-01 | PROCEDES ET COMPOSITIONS POUR RETABLIR LA STABILITE DE CONFORMATION D'UNE PROTEINE DE LA FAMILLE p53 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105599A true BG105599A (en) | 2002-02-28 |
Family
ID=22333594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105599A BG105599A (en) | 1998-12-02 | 2001-06-14 | METHOD AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20020048271A1 (fr) |
| EP (1) | EP1137418A2 (fr) |
| JP (2) | JP2002531396A (fr) |
| KR (1) | KR20010086073A (fr) |
| CN (1) | CN1329493A (fr) |
| AP (1) | AP2001002153A0 (fr) |
| AU (1) | AU1290700A (fr) |
| BG (1) | BG105599A (fr) |
| BR (1) | BR9915940A (fr) |
| CA (1) | CA2350597A1 (fr) |
| EA (1) | EA003326B1 (fr) |
| EE (1) | EE200100302A (fr) |
| HK (1) | HK1041644A1 (fr) |
| HR (1) | HRP20010414A2 (fr) |
| HU (1) | HUP0201215A2 (fr) |
| ID (1) | ID29061A (fr) |
| IL (1) | IL143094A0 (fr) |
| IS (1) | IS5943A (fr) |
| NO (1) | NO20012737L (fr) |
| OA (1) | OA11722A (fr) |
| PL (1) | PL348310A1 (fr) |
| TR (1) | TR200101549T2 (fr) |
| WO (1) | WO2000032175A2 (fr) |
| YU (1) | YU35401A (fr) |
| ZA (1) | ZA200104210B (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US20030022243A1 (en) * | 2001-06-20 | 2003-01-30 | Les Kondejewski | Protein aggregation assays and uses thereof |
| JP2005510460A (ja) * | 2001-08-10 | 2005-04-21 | メディカル リサーチ カウンシル | 分子 |
| WO2004034013A2 (fr) * | 2002-05-06 | 2004-04-22 | Colorado State University Research Foundation | Analyse de genotoxicite |
| AU2003258662A1 (en) * | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
| ES2272911T3 (es) * | 2003-04-25 | 2007-05-01 | Neurofit Sas | Uso de derivados de fenotiazina piperazina en la fabricacion de un medicamento con efectos neuroprotector y/o neurotroficos sobre cns y/o pns. |
| US6970791B1 (en) * | 2003-05-23 | 2005-11-29 | Verachem, Llc | Tailored user interfaces for molecular modeling |
| WO2005003100A2 (fr) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | Composes et leur utilisation therapeutique |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| WO2006074147A2 (fr) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Composes et utilisation therapeutique associee |
| EP1687275A4 (fr) * | 2003-11-21 | 2009-01-14 | Merck & Co Inc | Composes de pyridin-4-ylamine convenant pour le traitement de la douleur neuropathique |
| WO2005061007A1 (fr) * | 2003-12-24 | 2005-07-07 | St. Marianna University School Of Medicine | Procede d'extirpation d'un cancer |
| KR100809890B1 (ko) * | 2003-12-24 | 2008-03-06 | 가부시키가이샤 로코모젠 | 암 억제 방법 |
| CA2569404A1 (fr) * | 2004-06-04 | 2005-12-22 | Amphora Discovery Corporation | Composes a base de quinoleine et d'isoquinoleine presentant une activite d'inhibition d'enzymes utilisant de l'atp et compositions et utilisations de ceux-ci |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| US7790474B1 (en) | 2005-07-15 | 2010-09-07 | Schering Corporation | p53 modulators |
| MX2008000744A (es) * | 2005-07-15 | 2008-03-10 | Schering Corp | Derivados de quinazolina utiles en el tratamiento del cancer. |
| US8232298B2 (en) | 2006-03-22 | 2012-07-31 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between MDM2 and P53 |
| ATE470665T1 (de) | 2006-03-22 | 2010-06-15 | Janssen Pharmaceutica Nv | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| NZ546477A (en) * | 2006-04-07 | 2009-04-30 | Auckland Uniservices Ltd | 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy |
| CA2657246C (fr) | 2006-07-10 | 2017-10-31 | Donald Landry | Compositions anti-cocaine et traitement |
| WO2008155441A1 (fr) * | 2007-06-20 | 2008-12-24 | Marikki Laiho | Activateurs et leurs applications thérapeutiques |
| CN101903038A (zh) | 2007-07-10 | 2010-12-01 | 纽约市哥伦比亚大学信托人 | 蛋白的热稳定化 |
| ES2534899T3 (es) | 2007-08-06 | 2015-04-30 | Janssen Pharmaceutica, N.V. | Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53 |
| MX2011008195A (es) | 2009-02-04 | 2011-09-06 | Janssen Pharmaceutica Nv | Derivados de indol como agentes anticancer. |
| US20130102627A1 (en) * | 2010-04-09 | 2013-04-25 | The Brigham And Women's Hospital, Inc. | Acridines As Inhibitors Of Haspin And DYRK Kinases |
| US9221760B2 (en) | 2011-05-09 | 2015-12-29 | Van Andel Research Institute | Autophagy inhibitors |
| US9187439B2 (en) | 2011-09-21 | 2015-11-17 | Inception Orion, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
| CN102660257B (zh) * | 2012-05-22 | 2013-11-27 | 南京邮电大学 | 吩噻嗪基喹唑啉类荧光离子探针及其应用 |
| ES2708556T3 (es) | 2014-09-30 | 2019-04-10 | Diadem S R L | Anticuerpo que se une a un epítopo lineal de p53 humana y sus aplicaciones para diagnóstico |
| CN105399670B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 一种苯并(c)吖啶酰胺基硫脲衍生物及其制备方法和用途 |
| CN105418501B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途 |
| CN105399671B (zh) * | 2015-12-02 | 2018-04-17 | 广西中医药大学 | 7‑对甲苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途 |
| AU2017214733B2 (en) * | 2016-02-04 | 2022-09-29 | Yeda Research And Development Co. Ltd. | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53 |
| IL286839B (en) * | 2016-02-19 | 2022-08-01 | Pmv Pharmaceuticals Inc | Propyne-indole compounds |
| CN109694358B (zh) * | 2019-01-23 | 2022-02-08 | 广西师范大学 | 2-对硝苯乙烯基-4-取代氨基喹唑啉衍生物及其制备方法和应用 |
| SMT202500339T1 (it) | 2019-09-23 | 2025-11-10 | Pmv Pharmaceuticals Inc | Metodi e composti per ripristinare la funzione di p53 mutante |
| US12570645B2 (en) | 2020-06-22 | 2026-03-10 | Pmv Pharmaceuticals, Inc. | Uses of p53 x-ray co-crystal structures |
| US20210405056A1 (en) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Methods for detecting mutant p53 function |
| WO2021262484A1 (fr) | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Polythérapie pour le traitement du cancer |
| GB202111035D0 (en) * | 2021-07-30 | 2021-09-15 | Vestlandets Innovasjonsselskap As | Therapy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224784D0 (en) * | 1992-11-26 | 1993-01-13 | Univ Dundee | Cellular protein |
| WO1995024483A1 (fr) * | 1994-03-08 | 1995-09-14 | Scotgen Biopharmaceuticals, Inc. | Anticorps recombines humanises anti-fb5 |
| AU708829B2 (en) * | 1994-12-13 | 1999-08-12 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
| US6107332A (en) * | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
| US6270954B1 (en) * | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US5900360A (en) * | 1996-04-10 | 1999-05-04 | Welch; William J. | Correction of genetic defects using chemical chaperones |
| DE19624154A1 (de) * | 1996-06-18 | 1998-01-08 | Hoechst Ag | Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung |
| US5932613A (en) * | 1996-07-03 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Anticancer agents |
| US5958892A (en) * | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
| EP0923561B1 (fr) * | 1996-08-28 | 2002-10-23 | The Procter & Gamble Company | Inhibiteurs de metalloprotease heterocycliques |
| UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| US6387673B1 (en) * | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
| US6284923B1 (en) * | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| US6387903B1 (en) * | 1997-08-27 | 2002-05-14 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6380395B1 (en) * | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
| FI105554B (fi) * | 1998-05-13 | 2000-09-15 | Galilaeus Oy | Geenimuunnelluista Streptomyces galilaeus-kannoista saatavat hybridiantrasykliinit |
| US6395749B1 (en) * | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
| US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
| DE69921151T2 (de) * | 1998-08-12 | 2005-06-02 | Daiichi Pure Chemicals Co. Ltd. | Fluorszierende marker |
| SE9900941D0 (sv) * | 1998-12-23 | 1999-03-16 | Nomet Management Serv Bv | Novel retinoic acid derivatives and their use |
| US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
| FR2788696B1 (fr) * | 1999-01-26 | 2004-03-05 | Synthelabo | Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central |
| AU4564200A (en) * | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6406699B1 (en) * | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| WO2001028550A1 (fr) * | 1999-10-15 | 2001-04-26 | Mayo Foundation For Medical Education And Research | Anesthesiques topiques employes dans le traitement du cancer, les affections auto-immunes et l'ischemie |
| US6372785B1 (en) * | 2000-05-04 | 2002-04-16 | Keith Chan, President Globoasia, Llc | Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon |
| US6384049B1 (en) * | 2000-05-25 | 2002-05-07 | The Procter & Gamble Company | Cancer treatment |
| US6395771B1 (en) * | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
| US6391916B1 (en) * | 2000-07-21 | 2002-05-21 | The Hong Kong University Of Science And Technology | Enediyne derivatives |
-
1999
- 1999-12-01 HR HR20010414A patent/HRP20010414A2/hr not_active Application Discontinuation
- 1999-12-01 KR KR1020017006830A patent/KR20010086073A/ko not_active Ceased
- 1999-12-01 HU HU0201215A patent/HUP0201215A2/hu unknown
- 1999-12-01 HK HK02103378.4A patent/HK1041644A1/zh unknown
- 1999-12-01 AP APAP/P/2001/002153A patent/AP2001002153A0/en unknown
- 1999-12-01 EE EEP200100302A patent/EE200100302A/xx unknown
- 1999-12-01 JP JP2000584871A patent/JP2002531396A/ja active Pending
- 1999-12-01 TR TR2001/01549T patent/TR200101549T2/xx unknown
- 1999-12-01 CA CA002350597A patent/CA2350597A1/fr not_active Abandoned
- 1999-12-01 OA OA1200100136A patent/OA11722A/en unknown
- 1999-12-01 YU YU35401A patent/YU35401A/sh unknown
- 1999-12-01 CN CN99814010A patent/CN1329493A/zh active Pending
- 1999-12-01 EA EA200100502A patent/EA003326B1/ru not_active IP Right Cessation
- 1999-12-01 BR BR9915940-6A patent/BR9915940A/pt not_active IP Right Cessation
- 1999-12-01 AU AU12907/00A patent/AU1290700A/en not_active Abandoned
- 1999-12-01 WO PCT/IB1999/001916 patent/WO2000032175A2/fr not_active Ceased
- 1999-12-01 IL IL14309499A patent/IL143094A0/xx unknown
- 1999-12-01 ID IDW00200101178A patent/ID29061A/id unknown
- 1999-12-01 EP EP99956270A patent/EP1137418A2/fr not_active Withdrawn
- 1999-12-01 PL PL99348310A patent/PL348310A1/xx unknown
-
2001
- 2001-05-15 IS IS5943A patent/IS5943A/is unknown
- 2001-05-23 US US09/863,976 patent/US20020048271A1/en not_active Abandoned
- 2001-05-23 ZA ZA200104210A patent/ZA200104210B/en unknown
- 2001-06-01 NO NO20012737A patent/NO20012737L/no not_active Application Discontinuation
- 2001-06-14 BG BG105599A patent/BG105599A/xx unknown
-
2006
- 2006-01-06 JP JP2006001475A patent/JP2006166920A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200104210B (en) | 2003-02-24 |
| TR200101549T2 (tr) | 2001-11-21 |
| ID29061A (id) | 2001-07-26 |
| YU35401A (sh) | 2005-07-19 |
| EA003326B1 (ru) | 2003-04-24 |
| NO20012737D0 (no) | 2001-06-01 |
| HK1041644A1 (zh) | 2002-07-19 |
| NO20012737L (no) | 2001-07-09 |
| AU1290700A (en) | 2000-06-19 |
| OA11722A (en) | 2005-01-25 |
| US20020048271A1 (en) | 2002-04-25 |
| AP2001002153A0 (en) | 2001-06-30 |
| KR20010086073A (ko) | 2001-09-07 |
| WO2000032175A3 (fr) | 2000-08-03 |
| JP2002531396A (ja) | 2002-09-24 |
| EA200100502A1 (ru) | 2001-12-24 |
| PL348310A1 (en) | 2002-05-20 |
| HUP0201215A2 (en) | 2002-08-28 |
| WO2000032175A2 (fr) | 2000-06-08 |
| BR9915940A (pt) | 2001-09-11 |
| IL143094A0 (en) | 2002-04-21 |
| JP2006166920A (ja) | 2006-06-29 |
| CN1329493A (zh) | 2002-01-02 |
| HRP20010414A2 (en) | 2002-06-30 |
| IS5943A (is) | 2001-05-15 |
| EP1137418A2 (fr) | 2001-10-04 |
| CA2350597A1 (fr) | 2000-06-08 |
| EE200100302A (et) | 2002-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU35401A (sh) | POSTUPCI I PREPARATI ZA USPOSTAVLJANJE UJEDNAČENE STABILNOSTI PROTEINA IZ p53 FAMILIJE | |
| BE2015C026I2 (en) | 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens | |
| MX9702865A (es) | Agentes estrogenicos. | |
| YU38801A (sh) | Azabicikloalkani kao modulatori ccr5 | |
| TWI224595B (en) | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | |
| HUP0103617A2 (hu) | Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
| ZA979961B (en) | 5-HT1F agonists | |
| HUP0102334A3 (en) | Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing the compound | |
| DE69428334D1 (de) | Wässrige Lösungen enthaltend Inklusionskomplexe aus Benzothiophenderivaten und Cyclodextrinen | |
| DE60027913D1 (de) | 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz | |
| GB9802277D0 (en) | Stabilizer mixture for organic materials | |
| IL141080A0 (en) | Disubstituted maleimide derivatives and pharmaceutical compositions containing the same | |
| EE200200281A (et) | Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks | |
| NL1009876A1 (nl) | Synergistisch stabilisatormengsel op basis van polyalkyl-1-oxa-diazaspirodecaanverbindingen. | |
| AU2106001A (en) | Methods and compositions for screening for angiogenesis modulating compounds | |
| HUP9901389A3 (en) | Piperidine and pyrrolidine derivatives acting for the central nervous system, pharmaceutical compositions containing these compounds, preparation and use thereof | |
| WO2001004116A3 (fr) | Pyrrolidines et piperidines neurotrophiques et compositions et procedes correspondants | |
| ATE213944T1 (de) | Verwendung von immunomodulatoren | |
| DK0838469T3 (da) | 10,13,15-trioxatricyclo(9.2.1 9.6)-pentadecanon-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser | |
| WO2000078795A3 (fr) | Rufomycines et leurs derives utiles comme inhibiteurs de la proteine-1 associee a la resistance aux antibiotiques (mrp-1) | |
| NO20000519L (no) | 2-acylaminopropanaminer som takykininreseptorantagonister | |
| AU5999199A (en) | Novel antibodies, drugs containing these antibodies and methods for screening compounds by using these antibodies | |
| DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
| PL340459A1 (en) | Agonists of 5ht1f | |
| IT1299743B1 (it) | Cerniera per mobili |